Drug discovery is a complicated and resource demanding procedure that entails the identification of a molecular candidate meeting biological activity, chemical and synthesis viability. The classical computational drug discovery methods have the challenge of the chemical space in the form of its large size and the complexity of molecular optimization in combinatorics. It has been suggested in this work that a quantum-enhanced version of target drug discovery can be developed by combining latent evolutionary optimization with synthesis-determined molecular prioritization. Generative models represent molecules in a continuous latent space and can be used to evolve molecules efficiently with pharmacological aims. The quantum optimization algorithms are used to speed up the fitness assessment and multi-objective selection. The strategy that is proposed provides the advantages that optimized molecules do not just have to be biologically effective, but they must also be chemically synthesizable, which enhances the translational viability between in-silico designs and laboratory synthesis.
Drug discovery is a complicated and resource demanding procedure that entails the identification of a molecular candidate meeting biological activity, chemical and synthesis viability. The classical computational drug discovery methods have the challenge of the chemical space in the form of its large size and the complexity of molecular optimization in combinatorics. It has been suggested in this work that a quantum-enhanced version of target drug discovery can be developed by combining latent evolutionary optimization with synthesis-determined molecular prioritization. Generative models represent molecules in a continuous latent space and can be used to evolve molecules efficiently with pharmacological aims. The quantum optimization algorithms are used to speed up the fitness assessment and multi-objective selection. The strategy that is proposed provides the advantages that optimized molecules do not just have to be biologically effective, but they must also be chemically synthesizable, which enhances the translational viability between in-silico designs and laboratory synthesis.
Drug discovery for a given protein target is a complex, resource-intensive process, often requiring years of research and billions of dollars in investment. Computational techniques, particularly deep learning models, have accelerated molecular generation, but they remain constrained by classical computational limitations and reliance on known chemical patterns. To address these challenges, we propose a hybrid quantum conditional GAN with gradient penalty for drug design, integrating quantum computing to enhance exploration of the vast chemical space. The proposed approach leverages a hybrid classical and quantum generative model to create novel molecular structures while ensuring they adhere to chemical and pharmacological properties. By conditioning the generative model on protein target sequences, we improve molecular specificity, increasing the likelihood of discovering viable drug candidates. Our framework generates chemically valid, diverse, and target-specific molecules, offering a promising avenue for more efficient and precise data-driven drug discovery.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.
Deep generative chemistry models emerge as powerful tools to expedite drug discovery. However, the immense size and complexity of the structural space of all possible drug-like molecules pose significant obstacles, which could be overcome with hybrid architectures combining quantum computers with deep classical networks. As the first step toward this goal, we built a compact discrete variational autoencoder (DVAE) with a Restricted Boltzmann Machine (RBM) of reduced size in its latent layer. The size of the proposed model was small enough to fit on a state-of-the-art D-Wave quantum annealer and allowed training on a subset of the ChEMBL dataset of biologically active compounds. Finally, we generated 2331 novel chemical structures with medicinal chemistry and synthetic accessibility properties in the ranges typical for molecules from ChEMBL. The presented results demonstrate the feasibility of using already existing or soon-to-be-available quantum computing devices as testbeds for future drug discovery applications.
Quantum computing plays a significant role in simulating molecules and atoms and offers advantages in chemistry over classical computing. The potential of Quantum Machine Learning (QML) can be used in drug discovery, chemical reaction simulations, and Material design for pharmaceuticals. QML leverages quantum computing and advanced machine learning to accelerate the identification of drug candidates, predict molecular interactions, and optimize compounds. In this paper, we present a systematic review of the methods used for molecular property prediction and molecular generation using quantum machine learning. We have included the recent research, perspective, advantages, and challenges that must be addressed to achieve this task. The objective of this research is not only to discuss current strategies and methods used for drug discovery but also to promote interdisciplinary research in the field of quantum computing and chemistry for wellness.
The pharmaceutical sector faces escalating challenges in discovering feasible treatment agents, expediting research timelines, and enhancing the overall success rate of new drug initiatives. Emerging as a transformative technology, quantum computer technology offers innovative opportunities for addressing these problems through superior molecular modelling, simulation, and optimization capabilities relative to classical computational methods. This chapter will examine the contributions of quantum technology to the future development of new medicines. Using various quantum algorithms, an improved understanding of molecular structure, protein–ligand interactions, reaction kinetics, and the dynamics of biomolecules will allow improved prediction of drug behaviour and efficacy. In addition, this chapter will address the combined use of AI, quantum simulation and computational chemistry to increase speed around target identification; virtual screening; lead optimizing; and personalizing medicine creation.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.